Nanocoatings News February-March 2017

0

LiquiGlide Inc. has announced it is expanding its super-slippery coating platform beyond consumer packaging to focus on applications in manufacturing. With the patented LiquiGlide CleanTanX™ system, the company is providing a complete industry solution that addresses the manufacturing challenges created by viscous liquids sticking to equipment, such as blenders, reactors and tanks. In manufacturing tank applications, the system has been shown to reduce up to 95% of product waste, wash water and the associated cleaning costs.

MetaShield has developed its proprietary ‘MetaShieldPV’ nano-coating technology that increases solar cell efficiency using advanced light trapping. Upon application, the product solidifies in air at room temperature and forms a thin film layer with refractive index of ~1.5. MetaShieldPV is a patent pending formula that is spray coated directly onto the existing anti-reflective coating on the solar cells and hardens at room temperature, forming a transparent ~200nm glass film. The embedded nanoparticles employ strong forward scattering to affect optical enhancement in solar cells. An independent study via the Utah Science Technology and Research Initiative (USTAR) TAP program and and verified by OAI-Optical Associates boosted triple junction (GaInP/GaInAs/Ge) solar cell efficiency by 1.2% (absolute) from 29.39% to 30.59%. MetaSOL’s ability to provide a similarly dramatic enhancement to crystalline silicon photovoltaic cells is under development.

NEI Corporation has announced that the US Patent and Trademark Office (USPTO) has issued a notice of allowance to the company on two patent applications; one for a durable highly hydrophobic coating and the other for an adhesion promoting surface treatment. These patents complement NEI’s portfolio of patents pertaining to superhydrophobic, self-healing, and abrasion resistant coatings.

Semblant, a market leader in liquid damage nanotechnology for electronic devices, has signed production qualification agreements with three leading China smartphone manufacturers related to its patented MobileShield™ waterproofing technology.

Nanocoatings company NanoPhyll has received two purchase orders and is in discussions with strategic distribution partners with plans to commercialize their first product line in early 2017. The company’s self-cleaning technology is activated by the immediate environment — notably by natural light — eliminating the need for heavy detergents, surfactants and acids. Moreover, their coatings remove pollutants like nitrogen oxides from the air, helping to reduce smog and related acid rain.

NBD Nanotechnologies have introduced a new coating solution that renders fingerprints invisible on metal and glass surfaces. With the patented InvisiPrint™ solution, the company lets manufacturers successfully meet the long-standing demand by consumers for a solution that reduces or eliminates the appearance of fingerprints on products such as electronic displays, kitchen appliances, bathroom faucets, and automotive interiors.

Thomas Swan has announced the launch of a high-performance graphene intermediate product for coatings formulators. The new Elicarb Graphene product is a cost effective, stable, easy to handle dispersion of Elicarb Materials Grade Graphene powder for formulation into epoxy-based coating formulations. The product is available now in liter quantities for testing and evaluation.

CeloNova BioSciences, Inc. has received U.S. Food and Drug Administration (FDA) approval of its first-in-class COBRA PzF™ NanoCoated Coronary Stent System. Regulatory approval of the novel stent system was based on findings from the pivotal PzF SHIELD clinical trial, which successfully met its primary safety and effectiveness endpoints at 9-month follow-up, demonstrating no stent thrombosis and low clinically driven target lesion revascularization (TLR) of 4.6 percent.i Coated with a proprietary nano-thin polymer that is designed to be highly biocompatible, the COBRA PzF stent requires a minimum 30-day dual antiplatelet therapy (DAPT) regimen following intervention